- Home
- MYGN vs IFN Comparison
MYGN vs IFN Comparison
Compare MYGN & IFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- IFN
- Stock Information
- Founded
- MYGN 1991
- IFN 1993
- Country
- MYGN United States
- IFN Singapore
- Employees
- MYGN N/A
- IFN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IFN Finance/Investors Services
- Sector
- MYGN Health Care
- IFN Finance
- Exchange
- MYGN Nasdaq
- IFN Nasdaq
- Market Cap
- MYGN 642.0M
- IFN 595.7M
- IPO Year
- MYGN 1995
- IFN N/A
- Fundamental
- Price
- MYGN $7.40
- IFN $15.13
- Analyst Decision
- MYGN Hold
- IFN
- Analyst Count
- MYGN 13
- IFN 0
- Target Price
- MYGN $13.50
- IFN N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- IFN 135.2K
- Earning Date
- MYGN 11-06-2025
- IFN 01-01-0001
- Dividend Yield
- MYGN N/A
- IFN 8.68%
- EPS Growth
- MYGN N/A
- IFN N/A
- EPS
- MYGN N/A
- IFN N/A
- Revenue
- MYGN $832,900,000.00
- IFN N/A
- Revenue This Year
- MYGN $0.17
- IFN N/A
- Revenue Next Year
- MYGN $6.19
- IFN N/A
- P/E Ratio
- MYGN N/A
- IFN N/A
- Revenue Growth
- MYGN 3.83
- IFN N/A
- 52 Week Low
- MYGN $3.76
- IFN $14.40
- 52 Week High
- MYGN $29.30
- IFN $21.25
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- IFN 45.22
- Support Level
- MYGN $7.13
- IFN $14.93
- Resistance Level
- MYGN $7.80
- IFN $15.23
- Average True Range (ATR)
- MYGN 0.44
- IFN 0.15
- MACD
- MYGN 0.04
- IFN 0.02
- Stochastic Oscillator
- MYGN 78.61
- IFN 71.81
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About IFN India Fund Inc. (The)
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.